BMS - Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Dapagliflozin in Type 1 Diabetes

• Status: Completed
• Trial end date: 2012-10-01
• Target enrollment: 0
• Participant gender: All

Summary

To obtain safety and tolerability information in patients with type 1 diabetes where Dapagliflozin is added on to Insulin (for 14 days)

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Collaborator: Astra Zeneca, Bristol-Myers Squibb
• Treatments: Dapagliflozin

Criteria

Inclusion Criteria:

• Type 1 diabetes with central lab Glycosylated hemoglobin (A1C) ≥ 7.0% and ≤ 10.0%

• Insulin use for at least 12 months and initiation immediately after diagnosis of diabetes

• Method of Insulin administration [multiple daily injections (MDI) or continuous subcutaneous Insulin infusion (CSII)] stable ≥ 3 months

• Stable basal Insulin dose ≥ 2 weeks

• Ages 18 to 65 years

• Central laboratory C-peptide value of < 0.7 ng/mL

• Body mass index (BMI) 18.5 to 35.0 kg/m2

Exclusion Criteria:

• History of type 2 diabetes mellitus (T2DM), maturity onset diabetes of young (MODY), pancreatic surgery or chronic pancreatitis

• Oral hypoglycemic agents

• History of diabetes ketoacidosis (DKA) within 24 weeks

• History of hospital admission for glycemic control within 6 months

• Frequent episodes of hypoglycemia (2 unexplained within 3 months) or hypoglycemic unawareness

• Aspartate aminotransferase (AST), Alanine aminotransferase (ALT) or Serum total bilirubin > 2X Upper limit of normal (ULN)

• Abnormal Free T4 [if screening Thyroid Stimulating Hormone (TSH) abnormal]

• Estimated glomerular filtration rate (eGFR) Modification of Diet in Renal Disease (MDRD) formula ≤ 60 mL/min/1.73m2

• Cardiovascular (CV)/Vascular Diseases within 6 months